Comparison of the latest commercial short and long oligonucleotide microarray technologies
Open Access
- 15 March 2006
- journal article
- research article
- Published by Springer Nature in BMC Genomics
- Vol. 7 (1) , 51
- https://doi.org/10.1186/1471-2164-7-51
Abstract
Background: We compared the relative precision and accuracy of expression measurements obtained from three different state-of-the-art commercial short and long-oligonucleotide microarray platforms (Affymetrix GeneChip™, GE Healthcare CodeLink™ and Agilent Technologies). The design of the comparison was chosen to judge each platform in the context of a multi-project program.Results: All wet-lab experiments and raw data acquisitions were performed independently by each commercial platform. Intra-platform reproducibility was assessed using measurements from all available targets. Inter-platform comparisons of relative signal intensities were based on a common and non-redundant set of roughly 3,400 targets chosen for their unique correspondence toward a single transcript. Despite many examples of strong similarities we found several areas of discrepancy between the different platforms.Conclusion: We found a higher level of reproducibility from one-color based microarrays (Affymetrix and CodeLink) compared to the two-color arrays from Agilent. Overall, Affymetrix data had a slightly higher level of concordance with sample-matched real-time quantitative reverse-transcriptase polymerase chain reaction (QRT-PCR) data particularly for detecting small changes in gene expression levels.Keywords
This publication has 37 references indexed in Scilit:
- Addendum: Standardizing global gene expression analysis between laboratories and across platformsNature Methods, 2005
- Standardizing global gene expression analysis between laboratories and across platformsNature Methods, 2005
- Multiple-laboratory comparison of microarray platformsNature Methods, 2005
- Characterizing dye bias in microarray experimentsBioinformatics, 2005
- Increased measurement accuracy for sequence-verified microarray probesPhysiological Genomics, 2004
- Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer programLeukemia, 2003
- Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer ProgramLeukemia, 2003
- Evaluation of gene expression measurements from commercial microarray platformsNucleic Acids Research, 2003
- Amplification of the BCAS2 gene at chromosome 1p13.3–21 in human primary breast cancerCancer Letters, 2002
- Standards for Microarray DataScience, 2002